Amrinone inamrinone

Inamrinone (previously called amrinone) and milrinone are bipyridine compounds that inhibit phosphodiesterase isozyme 3 (PDE-3). They are active orally as well as parenterally but are available only in parenteral forms. They have elimination half-lives of 3-6 hours, with 10-40% being excreted in the urine. 

Inamrinone and milrinone are used occasionally short term. They inhibit PDE —>T cAMP, exerting positive inotropy and causing vasodilation. Amrinone causes thrombocytopenia milrinone decreases survival in heart failure ... 

Loops ethacrynic acid, furosemide, torsemide Bipyridines inamrinone, amrinone, milrmone, P agonists dobutamine, dopamine Statins lovastatin atorvastatin, etc Fibrates gemfibrozil... 

INAMRINONE AND MILRINONE Parenteral formulations of inamrinone (previous name amrinone) and milrinone are approved for short-term support of the circulation in advanced heart failure. Both drugs are bipyridine derivatives and relatively selective inhibitors of PDE3, the cyclic GMP-inhibited cyclic AMP PDE. These drugs cause direct stimulation of myocardial contractility and acceleration of myocardial relaxation. In addition, they cause balanced arterial and venous dilation with a consequent fall in systemic and pulmonary vascular resistances, and left and right heart filling pressures. Cardiac output increases due to the stimulation of myocardial contractility and the decrease in left ventricular afterload. As a result of this dual mechanism of action, the increase in cardiac output with milrinone is greater than that seen with nitroprusside at doses that comparably reduce systemic resistance. Conversely, the arterial and venous dilator effects of milrinone are greater than those of dobutamine at doses that produce comparable increases in cardiac output. 

F. Name changed from amrinone to inamrinone to prevent contusion with amio-darone. 

Section II Iron Section III Deferoxamine Inamrinone (Formerly Amrinone) Ipecac Syrup Kathy Marquardt, PharmD, DABAT... 

---